These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 37290104)
21. Uptake and efficacy of bilateral risk reducing surgery in unaffected female Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438 [TBL] [Abstract][Full Text] [Related]
22. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study. Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559 [TBL] [Abstract][Full Text] [Related]
23. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354 [TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers. Stroot IAS; Bart J; Hollema H; Jalving M; Wagner MM; Yigit R; van Doorn HC; de Hullu JA; Gaarenstroom KN; van Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez García EB; Ausems MGEM; Boere IA; van Hest LP; Duijkers FAM; van Asperen CJ; Schmidt MK; Wevers MR; Ruijs MWG; Devilee P; Collée JM; Hebon Investigators ; de Bock GH; Mourits MJE Gynecol Oncol; 2024 Aug; 187():198-203. PubMed ID: 38795508 [TBL] [Abstract][Full Text] [Related]
25. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995 [TBL] [Abstract][Full Text] [Related]
26. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111 [TBL] [Abstract][Full Text] [Related]
27. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014 [TBL] [Abstract][Full Text] [Related]
28. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P; Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637 [TBL] [Abstract][Full Text] [Related]
29. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487 [TBL] [Abstract][Full Text] [Related]
30. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374 [TBL] [Abstract][Full Text] [Related]
31. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study. Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390 [TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers. Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095 [TBL] [Abstract][Full Text] [Related]
33. Combined Bilateral Salpingo-oophorectomy and Cesarean Delivery in BRCA1/2 Alteration Carriers : A Case Series. Barker VE; Vlachodimitropoulou E; O'Brien P; Iskaros J; Rosenthal AN Obstet Gynecol; 2023 Dec; 142(6):1500-1503. PubMed ID: 37917945 [TBL] [Abstract][Full Text] [Related]
34. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636 [TBL] [Abstract][Full Text] [Related]
35. Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant. Zilski N; Speiser D; Bartley J; Roehle R; Blohmer JU; Keilholz U; Goerling U J Sex Med; 2023 Dec; 21(1):33-39. PubMed ID: 37973412 [TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999 [TBL] [Abstract][Full Text] [Related]
37. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257 [TBL] [Abstract][Full Text] [Related]
38. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754 [TBL] [Abstract][Full Text] [Related]
39. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397 [TBL] [Abstract][Full Text] [Related]
40. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy. DeLeo MJ; Domchek SM; Kontos D; Conant E; Chen J; Weinstein S AJR Am J Roentgenol; 2015 Mar; 204(3):669-73. PubMed ID: 25714301 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]